HYPD — Hyperion DeFi Share News
0.000.00%
- $39.22m
- $38.02m
- $0.81m
U.S. STOCKS ON THE MOVE-Ocugen, Model N, Fastly
Eyenovia rises on plans to explore strategic alternatives
Brief: Eyenovia Exploring Wide Range Of Strategic Alternatives
Eyenovia Inc reports results for the quarter ended in December - Earnings Summary
Eyenovia Inc expected to post a loss of 17 cents a share - Earnings Preview
Promote Prescription Ophthalmic Products To U.S. Eyecare Professionals
US FDA approves Eyenovia's eye drug, Formosa Pharma says (updated)
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%
Brief: Eyenovia Announces FDA Approval Of Redwood City As Commercial Manufacturing Facility
Brief: Eyenovia Re-Acquires Development And Commercialization Rights To Micropine In The U.S. And Canada
U.S. STOCKS ON THE MOVE-Kraft Heinz, Humana, Estee Lauder
Eyenovia rises as William Blair initiates coverage with 'outperform' rating
U.S. STOCKS ON THE MOVE-Nu Holdings, United States Steel, Mallinckrodt
U.S. STOCKS ON THE MOVE-Chevron, Coherent, HF Sinclair
U.S. STOCKS ON THE MOVE-Eyenovia, TJX Cos, H & R Block
Eyenovia rises on deal with Taiwan-based Formosa Pharma for eye treatment
Brief: Eyenovia Inc - Required To Pay Formosa $2 Mln Within 45 Days Of Effective Date Of Agreement
Brief: Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals